TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin Sells 48,515 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) Director James R. Tobin sold 48,515 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $39.98, for a total transaction of $1,939,629.70. Following the transaction, the director now directly owns 253,591 shares in the company, valued at $10,138,568.18. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $41.58 on Tuesday. TransMedics Group, Inc. has a 12 month low of $10.00 and a 12 month high of $42.00. The stock has a market cap of $1.16 billion, a PE ratio of -24.46 and a beta of 1.63. The company has a current ratio of 5.22, a quick ratio of 4.40 and a debt-to-equity ratio of 0.59. The company’s fifty day moving average price is $31.30 and its 200-day moving average price is $24.54.

TransMedics Group (NASDAQ:TMDXGet Rating) last announced its earnings results on Tuesday, May 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). TransMedics Group had a negative net margin of 119.88% and a negative return on equity of 63.47%. The business had revenue of $15.88 million for the quarter, compared to the consensus estimate of $10.22 million. During the same quarter last year, the firm posted ($0.29) EPS. On average, equities analysts expect that TransMedics Group, Inc. will post -1.42 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on TMDX shares. Morgan Stanley boosted their price objective on shares of TransMedics Group from $25.00 to $34.00 and gave the company an “equal weight” rating in a research report on Wednesday, June 29th. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $39.00 to $46.00 in a research report on Wednesday, May 4th. Cowen boosted their price objective on shares of TransMedics Group from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, July 26th. Finally, Cowen boosted their price objective on shares of TransMedics Group from $39.00 to $45.00 and gave the company a “maintains” rating in a research report on Tuesday, July 26th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $36.83.

Institutional Trading of TransMedics Group

A number of hedge funds have recently modified their holdings of TMDX. Envestnet Asset Management Inc. boosted its stake in TransMedics Group by 1.8% in the 4th quarter. Envestnet Asset Management Inc. now owns 54,236 shares of the company’s stock worth $1,039,000 after purchasing an additional 949 shares in the last quarter. Sandhill Capital Partners LLC boosted its stake in TransMedics Group by 25.4% in the 4th quarter. Sandhill Capital Partners LLC now owns 1,805,518 shares of the company’s stock worth $34,594,000 after purchasing an additional 365,473 shares in the last quarter. HarbourVest Partners LLC bought a new position in TransMedics Group in the 4th quarter worth about $2,225,000. Moody Aldrich Partners LLC boosted its stake in TransMedics Group by 24.1% in the 4th quarter. Moody Aldrich Partners LLC now owns 166,078 shares of the company’s stock worth $3,182,000 after purchasing an additional 32,209 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC boosted its stake in TransMedics Group by 29.4% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 266,231 shares of the company’s stock worth $5,101,000 after purchasing an additional 60,507 shares in the last quarter. Institutional investors own 71.75% of the company’s stock.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Articles

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Want More Great Investing Ideas?

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.